Clinical Trial Detail

NCT ID NCT02940301
Title Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Ohio State University Comprehensive Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Ibrutinib + Nivolumab

Age Groups: adult senior

No variant requirements are available.